Pulmatrix, Inc. (PULM) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.29

From 52W high−73.11%

Volume116482.00

Market cap$4.80M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.29

From 52W high

−73.11%

Volume

116482.00

Market cap

$4.80M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

30.8

MomentumView details →

1D Return

−1.14%

YTD Return

−49.33%

SummaryUpdated Jun 1, 2026

Pulmatrix, Inc. (NASDAQ:PULM) is a clinical-stage biotechnology company founded in 2003 and headquartered in Lexington, Massachusetts. The company went public in March 2014 and specializes in developing inhaled therapies for respiratory and other diseases with significant unmet medical needs. Pulmatrix focuses on leveraging its proprietary drug delivery platform to create innovative treatments that can be administered directly to the lungs through inhalation.

Ask drillr about Pulmatrix, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−156.94%

ROA (TTM)

−123.63%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+49.07%

FCF YoY

+51.22%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+46.18%

EBITDA YoY

+49.16%

MomentumView details →

1D Return

−1.14%

YTD Return

−49.33%

1Y Return

−76.60%

RSI (14)

30.8

vs 50D SMA

−23.23%

vs 200D SMA

−33.13%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

4.70x

Quick Ratio

4.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.29

EPS Surprise

85.50%

Beats (12Q)

4/12

Next Q EPS Est

−$1.80

Avg Surprise (4Q)

26.71%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−4.01M

Op. CF (TTM)

−3.91M

Next earningsNov 5, 2026 →

Latest newsMore news →

Eos SENOLYTIX said it anticipates closing its merger with Pulmatrix, Inc. in the fourth quarter, subject to customary closing conditions.43d ago

Pulmatrix announced its second quarter 2026 financial results and provided an update on its merger agreement with Eos SENOLYTIX, including the filing of a Form S-4.83d ago

Similar companies

Galmed Pharmaceuticals Ltd.GLMD Xenetic Biosciences, Inc.XBIO Cardio Diagnostics Holdings, Inc.CDIO Medicus Pharma Ltd.MDCXW Creative Medical Technology Holdings, Inc.CELZ Niki BioSolutions, Inc.NIKI Find similar companies →

Latest newsMore news →

Eos SENOLYTIX said it anticipates closing its merger with Pulmatrix, Inc. in the fourth quarter, subject to customary closing conditions.43d ago Pulmatrix announced its second quarter 2026 financial results and provided an update on its merger agreement with Eos SENOLYTIX, including the filing of a Form S-4.83d ago